Sunshine Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sunshine Biopharma (SBFM).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingBuy# Analysts1Avg. Consensus PT$70Upside to Avg. PT+18379.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 8, 2025	Aegis Capital	David Bouchey	Maintained	Buy	$7
Dec 5, 2024	Aegis Capital	David Bouchey	Maintained	Buy	$15

Analyst Ratings News

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $7 price target.

Benzinga Newsdesk

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.

Rishabh Mishra

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma (NASDAQ:SBFM) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

Aegis Capital analyst David Bouchey initiates coverage on Sunshine Biopharma (NASDAQ:SBFM) with a Buy rating and announces Price Target of $2.6.

Benzinga Newsdesk

Sunshine Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Sunshine Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

People Also Watch

People Also Watch

Sunshine Biopharma Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Sunshine Biopharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia

PROAegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PROAegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6

People Also Watch

People Also Watch

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

PRO
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $15 Price Target

PRO
Aegis Capital Initiates Coverage On Sunshine Biopharma with Buy Rating, Announces Price Target of $2.6